Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Cara Therapeutics partners CR845 with Maruishi in Japan

Executive Summary

Cara Therapeutics Inc. (candidates for pain, inflammation, and itching) has licensed Maruishi Pharmaceutical Co. Ltd. (perioperative and disinfecting/antiseptic products) exclusive Japanese rights to develop, manufacture, and market its most advanced compound CR845 for acute postoperative pain and uremic pruritus (itching in patients with end-stage renal disease).
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies